Takeda withdraws Actos in France as it awaits EMA decision
This article was originally published in Scrip
Executive Summary
Takeda is withdrawing its pioglitazone-containing products Actos and Competact in France, at the request of Afssaps, the French health regulatory authority. This follows Afssaps' recent decision to suspend the use of pioglitazone containing products for the treatment of type 2 diabetes. The same decision was taken shortly after by the German authorities, although the Japanese drug-maker has yet to announce a similar move in Germany.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.